Clinical Pathology

SNBL Japan can test for all parameters listed in the following guidelines for repeated dose toxicity studies.

The Amendment to the Guidelines for Repeated Dose Toxicity Studies (Notification No. 655 of the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, Japan, April 5, 1999)

We can also perform analyses of the parameters listed below.

Please contact us for more details.

Urinalysis

Protein, β2-microglobulin, Albumin, cystatin C, KIM-1, clusterin

These new biomarkers as identified by the FDA or EMEA can be analyzed in accordance with GLP regulations.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116911.htm

Coagulation and Fibrinolysis

Platelet aggregation, fibrinogen, fibrin degradation products, D-dimer, TAT, PAI-1, PIC, and bleeding time

Other Blood Components

Whole blood methemoglobin concentration, whole blood calcium ion, hemoglobin A1c, blood gas, and erythrocyte sedimentation rate

Blood Biochemistry

We offer fractional analyses including; lipid fractions, lipoprotein fractions, LDH isoenzyme, ALP isoenzyme, and CPK isoenzyme

Cardiovascular biomarkers

Troponin T, Troponin I, H-FABP, ANP, NTproBNP, and adiponectin

Bone Metabolism Markers

CTX, NTX, TRACP 5b, and P1NP

Bone Marrow

Bone marrow cell count and fractionation analysis

Other Special Examinations

Measurement of liver lipid and glycogen

Hepatic drug-metabolizing enzyme activity (sample preparation and analysis are performed at our Pharmacokinetics and Bioanalysis Center in Wakayama Prefecture )